{
    "pmcid": "7844813",
    "summary": "The paper titled \"Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein\" focuses on the development of nanobodies that target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein to block its interaction with the ACE2 receptor, thereby inhibiting viral entry into host cells. Here is a detailed summary with a focus on the SARS-CoV-2 spike protein and the design of nanobody binders:\n\n### SARS-CoV-2 Spike Protein\n\n1. **Structure and Function**: \n   - The spike (S) protein of SARS-CoV-2 is a key structural protein that facilitates viral entry into host cells. It forms a homotrimer protruding from the viral envelope, giving coronaviruses their characteristic crown-like appearance.\n   - The S protein is divided into two subunits: S1 and S2. The S1 subunit contains the RBD, which is responsible for binding to the ACE2 receptor on host cells. The S2 subunit is involved in membrane fusion, a critical step for viral entry.\n   - The RBD is a prime target for neutralizing antibodies because it is essential for the virus to attach to and enter host cells.\n\n2. **Immunogenicity**:\n   - The RBD is highly immunogenic and can induce the production of neutralizing antibodies. This makes it an attractive target for vaccine and therapeutic antibody development.\n\n### Design of SARS-CoV-2 Nanobody Binders\n\n1. **Nanobody Characteristics**:\n   - Nanobodies are single-domain antibodies derived from camelids, known for their small size, high stability, and ability to bind antigens with high specificity and affinity.\n   - They offer advantages such as better tissue penetration and lower immunogenicity compared to conventional antibodies.\n\n2. **Screening and Selection**:\n   - The study utilized a na\u00efve VHH library derived from Bactrian camels to screen for nanobodies that bind specifically to the SARS-CoV-2 spike protein and its RBD.\n   - Four specific nanobodies were identified: Nb91-hFc and Nb3-hFc showed significant antiviral activity by neutralizing spike pseudotyped viruses in vitro.\n\n3. **Multivalent Nanobody Construction**:\n   - To enhance neutralizing capacity, multivalent nanobodies were constructed. These included homodimers, heterodimers, and homotrimers.\n   - The heterodimer Nb91-Nb3-hFc exhibited the strongest RBD-binding affinity and neutralizing ability against SARS-CoV-2 pseudoviruses, with an IC50 value of approximately 1.54 nM.\n\n4. **Expression and Purification**:\n   - Nanobodies were expressed as fusion proteins with human Fc domains to increase their size and half-life, facilitating purification and enhancing their therapeutic potential.\n   - The expression system used HEK293FT cells, and the nanobodies were purified using Ni-NTA affinity chromatography.\n\n5. **Neutralization Assays**:\n   - The neutralizing activity of the nanobodies was assessed using a pseudovirus system. The pseudoviruses mimic the entry process of natural SARS-CoV-2, allowing for safe and effective evaluation of neutralization potential.\n   - Nb91-hFc and Nb3-hFc demonstrated effective neutralization, with the multivalent constructs showing significantly improved potency.\n\n6. **Potential Therapeutic Application**:\n   - The study suggests that the heterodimer Nb91-Nb3-hFc could serve as a potential therapeutic agent for COVID-19 treatment.\n   - The small size and stability of nanobodies make them suitable for various delivery methods, including aerosolized inhalation, which could be advantageous for respiratory infections like COVID-19.\n\n7. **Considerations for Development**:\n   - While nanobodies have a shorter circulation half-life due to their small size, strategies such as PEGylation or fusion with larger proteins can extend their half-life.\n   - The study emphasizes the potential of nanobodies for rapid development and deployment in response to emerging viral threats.\n\nIn conclusion, the paper highlights the potential of nanobodies as effective neutralizing agents against SARS-CoV-2 by targeting the RBD of the spike protein. The development of multivalent nanobodies enhances their neutralizing capacity, making them promising candidates for therapeutic applications in COVID-19.",
    "title": "Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein"
}